Last $71.00 USD
Change Today +0.48 / 0.68%
Volume 1.7M
As of 8:04 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ASTRAZENECA PLC-SPONS ADR (AZN) in the last 6 months

Announced 07/30/14
2.10B for Almirall, S.A. Respiratory Franchise
Merger/Acquisition

AstraZeneca PLC (LSE:AZN) entered into agreement to acquire respiratory franchise from Almirall, S.A. (CATS:ALM) for $2.1 billion on July 30, 2014. The franchise includes Eklira (aclidinium); LAS40464, LAS100977 (abediterol), LAS191351, LAS194871 and Phase I LAS190792 and multiple pre-clinical programmes. The initial consideration includes payment of $875 million on completion, and up to $1.22 billion in development, launch and sales-related milestones. AstraZeneca has ...
Read More


AZN's price was unchanged after the transaction was announced on 07/30/14.
Investor / Buyer
AstraZeneca PLC
Creditor / Lender
Almirall, S.A.
 
Announced 04/28/14
75.55B for AstraZeneca PLC
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) made a possible offer to acquire AstraZeneca PLC (LSE:AZN) from BlackRock, Inc. (NYSE:BLK) and others for £62.7 billion on April 26, 2014. Pfizer is considering a possible transaction, to be paid in a combination of cash and shares in the combined entity. Pfizer Inc. will pay £15.9 per share as cash and 1.845 stocks per share of AstraZeneca PLC. The transaction, if consummated, is expected to result in the combination of the two companies under ...
Read More


AZN's price was unchanged after the transaction was announced on 04/28/14.
 
Announced 04/28/14
64.17B for AstraZeneca PLC
Merger/Acquisition

Pfizer Inc. (NYSE:PFE) made a preliminary and conditional proposal to acquire AstraZeneca PLC (LSE:AZN) for £58 billion in cash and stock on January 5, 2014. Under the terms, Pfizer would pay £13.98 in cash and issue 1.758 Pfizer shares for each share of AstraZeneca. The combined company will be listed and headquartered in United States. Fares Noujaim, Adrian Mee, Michael Findlay and Geoff Iles of Merrill Lynch, Pierce, Fenner & Smith Inc and Merrill Lynch International ...
Read More


AZN's price was unchanged after the transaction was announced on 04/28/14.
 
Announced 04/24/14
AstraZeneca PLC
Buyback

AstraZeneca plc (LSE:AZN) announces a share repurchase program. Under the program, the company will repurchase up to 126,096,700 shares, representing 10% of its issued capital. The minimum price (exclusive of expenses) which may be paid for each ordinary share is $0.25. The maximum price (exclusive of expenses) which may be paid for each ordinary share is the higher of either an amount equal to 105% of the average of the middle market quotations for an ordinary share ...
Read More


AZN's price was unchanged after the transaction was announced on 04/24/14.
 
Announced 03/11/14
AstraZeneca PLC, Alderley Park Site in Cheshire
Merger/Acquisition

Manchester Science Park Ltd. agreed to acquire Alderley Park site in Cheshire from AstraZeneca PLC (LSE:AZN) on March 11, 2014. The transaction is expected to close by the end of March 2014. Funding for the deal was provided by Bruntwood, MSP and Cheshire East Council, with Bruntwood as the majority funder. JLL acted as real estate advisor to AstraZeneca in the transaction. Michael Birchall and Stephen Kinsey of Addleshaw Goddard Ltd. acted as legal advisor to Manchester ...
Read More


AZN's price was unchanged after the transaction was announced on 03/11/14.
Investor / Buyer
Manchester Science Parks Limited
Creditor / Lender
AstraZeneca PLC
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:US $71.00 USD +0.48

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AZN.
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
No financial data is available for AZN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.